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Background: Napsin A, an aspartic protease, is mainly expressed in alveolar type-II cells and renal proximal tubules
and is a putative immunohistochemical marker for pulmonary adenocarcinomas. This study sought to determine
whether napsin A could be measured in the serum to evaluate its relationship to idiopathic pulmonary fibrosis (IPF)
and determine whether renal dysfunction might affect serum napsin A levels.
Methods: Serum levels of napsin A were measured in 20 patients with IPF, 34 patients with lung primary
adenocarcinoma, 12 patients with kidney diseases, and 20 healthy volunteers. Surfactant protein (SP)-A, SP-D, and
Krebs von den Lungen-6 (KL-6) levels in serum and pulmonary function tests were also evaluated in IPF patients.
Results: Circulating levels of napsin A were increased in patients with IPF, as compared with healthy controls, and
they correlated with the severity of disease. Moreover, the serum napsin A levels were not elevated in patients with
pulmonary adenocarcinoma or renal dysfunction. The distinguishing point between IPF and the controls was that
the area under the receiver operating characteristic curve (ROC) of napsin A was larger than that of KL-6, SP-A, or
SP-D.
Conclusion: These findings suggest that serum napsin A may be a candidate biomarker for IPF.
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Idiopathic pulmonary fibrosis (IPF), a chronic, progres-
sive, fibrotic interstitial lung disease (ILD) with a poor
prognosis, is largely unaffected by currently available
medical treatments [1]. IPF is associated with the histo-
pathologic and/or radiologic pattern of a usual intersti-
tial pneumonia (UIP). It is characterized by progressive
worsening of dyspnea and lung function. The incidence
and mortality of IPF are increasing [1,2], and the median
survival time is 2 to 3 years from the time of diagnosis
[3]. Identification of peripheral blood biomarkers may
facilitate the diagnosis, estimation of prognosis, and se-
lection and evaluation of a treatment as well as the* Correspondence: inoue-pulm@umin.net
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distribution, and reproduction in any mediumdevelopment of new therapeutic intervention. A number
of candidate blood biomarkers for IPF including cyto-
kines, chemokines, enzymes, collagen relevant products
and products of type II epithelial cells, have been studied
for their diagnostic and predictive values. Serum levels
of mucin-like glycoprotein Krebs von den Lungen 6 anti-
gen (KL-6) [4], surfactant protein (SP)-A and SP-D [5,6],
matrix metalloproteinase (MMP)1 and MMP7 [7], brain
natriuretic peptide [8], and, most recently CC-
chemokine ligand 18 [9] are elevated in patients with
IPF. KL-6, SP-A, and SP-D in blood are considered to
derive from proliferating epithelial cells and/or disrup-
tion of the epithelial barrier.
Napsin A, an aspartic proteinase, is expressed in type
II pneumocytes and in alveolar macrophages presumably
secondary to phagocytosis [10,11]. It is abundant and ac-
tive in the alveolar space, correlating with the levels of
SP-B, proSP-B, and SP-C [11]. Therefore, it is possibletral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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pneumocyte hyperplasia and/or epithelial barrier break-
down, such as IPF and acute lung injury. In addition,
immunohistochemistry for napsin A marks most cases
of lung adenocarcinomas and is negative in most squa-
mous cell carcinomas and adenocarcinomas of other
organs [12,13]. Its local expression is reported to be use-
ful both for classifying primary lung tumors as adenocar-
cinoma and for identifying lung origin in the setting of a
metastatic adenocarcinoma [12,13].
We hypothesized that serum napsin A levels would be
increased in patients with IPF and would correlate with
severity of disease [14,15]. To test this hypothesis, we
quantitated levels of circulating napsin A in patients
with IPF, primary pulmonary adenocarcinomas, and con-
trols, after that we analyzed the correlations between the
serum levels of napsin A and those of KL-6, SP-A, SP-D
respectively, and lung function as measured by percent-
predicted forced vital capacity (FVC) in IPF patients.
Furthermore, napsin A is also expressed in the proximal
convoluted tubules of the kidney [10], and we measured
serum napsin A levels in patients with kidney disease to




We evaluated 40 ILD patients according to a flowchart,
Diagnostic Process in diffuse pulmonary lung diseases
(DPLD) (2002) [16]. Of these 40 patients, 10 patients were
excluded due to collagen vascular disease. Of the
remaining 30 patients, who were regarded as having idio-
pathic interstitial pneumonia (IIP), 17 patients were diag-
nosed with IPF based on history, physical examination,
pulmonary function tests, arterial blood gas analysis, and
high-resolution computed tomography of the chest. The
other 13 patients underwent biopsy. Of these 13 patients,
three had UIP and ten had non-UIP; of the non-UIP
patients, eight had nonspecific interstitial pneumonia and
two had cryptogenic organizing pneumonia. The three
UIP patients were clinically consistent with a diagnosis of
IPF. Consequently, 20 (17+ 3) patients met the consensus
definition of IPF in accordance with Diagnostic Process in
DPLD. The biopsy rates were 43% (13/30) for IIP patients
and 15% (3/20) for the 20 patients in whom IPF were sus-
pected. Serum samples were collected from 20 patients
with IPF (18 males and 2 females, mean age,
72.4 ± 5.3 yr), 34 patients with primary lung adenocarcin-
oma without ILD (18 males and 16 females, mean age,
68.9 ± 9.4 yr), 12 patients with kidney disease (4 males
and 8 females, mean age, 44.3 ± 18.2 yr), and 20 control
subjects (10 males and 10 females, mean age,
60.0 ± 4.6 yr). Pulmonary function was measured by spir-
ometry, and the mean percent-predicted FVC of IPFpatients was 74.0± 15.7%. In 16 of 20 IPF patients, spir-
ometry and measurement of serum napsin A were per-
formed at the same time points. All patients in the lung
cancer group underwent surgery, allowing determination
on histological features and surgical TNM criteria. The
patients with primary lung adenocarcinoma included thir-
teen with stage IA disease, three with stage IB, seven with
stage IIA, seven with stage IIIA, three with stage IIIB, and
one with stage IV. Preoperative serum samples were col-
lected from patients with lung cancer. Patients with kid-
ney disease included four with lupus nephritis, three with
IgA nephropathy, two with anti-neutrophil cytoplasmic
autoantibody (ANCA)-associated nephropathy, one with
diabetic nephropathy, one with amyloid nephropathy, and
one with interstitial nephritis in Sjogren syndrome. The
mean serum creatinine level in all patients with kidney
disease was 2.1 ± 1.4 mg/dl. The 20 control subjects were
healthy volunteers with no evidence of comorbidity. This
study was approved by the ethics committee of the Kago-
shima University Graduate School of Medical and Dental
Sciences (Number 21–48), and informed, written consent
was obtained from patients.
Measurements of napsin A, KL-6, SP-D, and SP-A
Serum samples collected from all groups prior to the 2011
release of guidelines, and all samples were stored at – 80°
C until use. Subsequent analysis was blinded to clinical
status. Levels of napsin A in sera were quantified by
sandwich-type enzyme-linked immunosorbent assay,
using commercially available ELISA kit (Human Napsin A
Assay Kit-IBL, Japan). Serum samples with napsin A levels
exceeding the top value of standard curve for the kits
value were diluted and reassayed. Serum KL-6, SP-D, and
SP-A were measured using commercially available ELISA
kits (Eitest KL-6 kit, Sanko Junyaku, Tokyo, Japan; SP-D
kit, YAMASA EIA, Yamasa, Japan; SP-A test Kokusai-F
kit, International Reagents Corporation, Japan) [17-19].
Statistical analysis
Data are expressed as means ± standard deviations. Dif-
ferences in serum levels of each marker between subject
groups were analyzed by ANOVA with Scheffe post hoc
test or by the Student’s t-test. Serum levels of napsin A,
KL-6, SP-A, and SP-D were further analyzed using a
ROC curve to determine the appropriate cut-off level
resulting in optimal diagnostic accuracy. Correlation was
performed using Spearman’s rank order correlation. Sig-
nificance was defined as p < 0.05.
Results
Serum napsin A was elevated in IPF but not in
adenocarcinoma or kidney disease
No significant difference was found between in age
between IPF and lung cancer patients. There were
Figure 2 ROC curves using napsin A, KL-6, SP-A, and SP-D as
serum markers for IPF in comparison with controls.
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and IPF patients and between control subjects and lung
cancer patients, and in gender among the groups. How-
ever, no correlation was found between serum napsin A
level and age, or gender in control subjects.
Serum Napsin A, KL-6, SP-D, and SP-A levels
(Figure 1) were significantly higher in IPF patients than
in control subjects and in lung cancer patients. Serum
napsin A, KL-6, and SP-A levels were also significantly
higher in IPF patients than in patients with lung cancer.
The diagnostic values for serum napsin A, KL-6, SP-A,
and SP-D for IPF vs control subjects were evaluated
from the ROC curves (Figure 2). The areas under the
ROC curves for IPF patients in comparison with control
subjects were 0.988 for napsin A, 0.938 for KL-6, 0.931
for SP-A, and 0.940 for SP-D, with serum napsin A
levels showing the greatest area, however, there were no
significant differences in AUC values between serum
napsin A and the other markers. The diagnostic cut-off
levels using ROC curves were set at 78.5 ng/ml for Nap-
sin A, 555.0 ml/UL for KL-6, 42.8 ng/ml for SP-A and
131.0 ng/ml for SP-D. For the diagnosis of IPF, the diag-
nostic accuracy of each marker determined from these
cut-off levels were, 95.0% for napsin A, 85.0% for KL-6,
85.0% for SP-A, and 92.5% for SP-D. All these serum
aids returned low false-positive rates in the diagnosis of




































Figure 1 Distribution of serum napsin A (A), KL-6 (B), SP-A (C), and SP
patients with primary pulmonary adenocarcinoma (lung cancer, n = 3
represents the diagnostic cut-off level (78.5 ng/ml for napsin A, 555.0 U/ml
pulmonary fibrosis; SP-A, surfactant protein A; SP-D, surfactant protein D. **napsin A and SP-D, 5% (1/20) for KL-6, and 15% (3/20)
for SP-A. SP-A showed the highest false positive rates in
the diagnosis IPF vs control; false-positive rates for SP-A








































-D (D) levels in patients with interstitial lung disease (IPF, n = 20),
4), and healthy volunteers (control, n = 20). Each horizontal line
for KL-6, 42.8 ng/ml for SP-A, and 131.0 ng/ml for SP-D). IPF, idiopathic
: p < 0.01. n.s.: not significant.
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with lung cancer were 5.8% (2/34) for napsin A, 2.9% (1/
34) for KL-6 and 8.8% (3/34) for SP-D.
The diagnostic values of serum napsin A, KL-6, SP-A,
and SP-D as specific markers to distinguish IPF from
lung cancer were determined from the ROC curves
(Figure 3). AUC values were 0.974 for napsin A, 0.975
for KL-6, 0.810 for SP-A, and 0.922 for SP-D. Napsin A
and KL-6 were of greater use than SP-A and SP-D as
serum markers to discriminate IPF from primary lung
adenocarcinoma. As tumor markers for lung adenocar-
cinoma, these showed no significant difference in lung
cancer vs control subjects (Figure 1). The cut-off levels
for napsin A and AUC obtained from the ROC curve
were 78.5 and 0.988 for IPF vs control and 76.4 and
0.974 for IPF vs lung cancer. None of the patients with
kidney disease showed significant elevation of serum
napsin A level in a comparison with the control subjects
(Figure 4).Serum napsin A levels correlate with those of KL-6, SP-A,
and SP-D in patients with IPF
In patients with IPF, there were significant correlations
between the serum napsin A levels and those of KL-6,
SP-A, and SP-D (Figure 5). The correlation between
napsin A levels and KL-6 levels (r = 0.611, p < 0.01), SP-
A levels (r = 0.760, p < 0.01), SP-D levels (r = 0.730,
p < 0.01) respectively. The serum napsin A levels in
patients with IPF were more strongly correlated with
SP-A and SP-D levels than with KL-6 levels.Figure 3 ROC curves using napsin A, KL-6, SP-A, and SP-D as
serum markers for IPF in comparison with lung cancer.Napsin A levels correlate with IPF severity
To determine whether napsin A levels correlate with
disease severity, we compared pulmonary function mea-
surements with serum concentrations of napsin A in IPF
patients. There was moderate inverse correlation be-
tween the napsin A level and lung function as measured
by percent-predicted FVC (Spearman r =−0.53, p < 0.05)
(Figure 6). We did not find any statistically significant
correlation between the napsin A levels and forced ex-
piratory volume in one second (FEV1) values (data not
shown).
Discussion
In the present study we demonstrated that circulating
levels of napsin A are increased in patients with IPF, as
compared with healthy controls, and correlate with
those of KL-6, SP-A, SP-D, and the severity of disease.
In addition, the serum napsin A levels were not elevated
in patients with pulmonary adenocarcinoma without
ILD or in kidney disease. These findings suggest that
serum napsin A may be a candidate biomarker for IPF.
Our findings demonstrating elevated serum levels of
KL-6, SP-A, and SP-D in IPF are consistent with those
reported previously [4-6], as well as the cut-off levels in
this study for KL-6, SP-A and SP-D were similar to those
in previous reports [17-19]. Compared to these serum
markers, napsin A showed the largest AUC for distin-
guishing IPF from controls. A comparison of KL-6,
SP-A, and SP-D for the diagnostic values in patients
with ILD including IPF previously demonstrated that
KL-6 was superior to other markers [6], and the findings
of present study for IPF regarding the order of the AUC
values obtained from ROC curves is the same as that
study [6], in which KL-6 preceded SP-A and SP-D. InFigure 4 Distribution of serum napsin A levels in 12 patients
with kidney disease and 20 control subjects. Mean level of
serum creatinine of all patients with kidney disease was
2.1 ± 1.4 mg/dl. n.s.: not significant.
Figure 5 Correlation between napsin A levels and KL-6 levels (Spearman r = 0.611, P < 0.01, A), SP-A levels (Spearman r = 0.706 P< 0.01,
B), and SP-D levels (Spearman r = 0.730, P < 0.01, C) in patents with IPF.
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nostic accuracy for distinguishing IPF from controls.
The mechanism by which the circulating levels of nap-
sin A are elevated in IPF is not known. It is probably
due to a combination of a loss of integrity of theFigure 6 Inverse correlation between napsin levels and lung
function as measured by percent-predicted FVC (% FVC)
(n = 16, r =− 0.53, p < 0.05).epithelial barrier caused by lung injury and an increased
mass of type II cells due to hyperplasia as SP-A and SP-
D [20]. The molecular weights of SP-A and SP-D are
26–38 kDa and 43 kDa, respectively [20-22]; that of nap-
sin A is approximately 38 kDa [12], while that of KL-6 is
estimated to be greater than 200 kD [20,23]. Serum
KL-6 possibly requires cleavage by a proteinase to liber-
ate its extracellular domain in order to leak into the
bloodstream [20,24]. These differences may account for
differences in the detected levels of these markers in
IPF.
Serum napsin A levels were correlated with serum
KL-6, SP-A, and SP-D in patients with IPF. Moreover, we
found that napsin A levels were more strongly correlated
with SP-A, and SP-D levels than with KL-6 levels, and this
is supported by previous findings that napsin A is protease
that relates to maturation of SP-B and SP-C [11]. Conse-
quently, napsin A is also a useful type II pneumocytes
marker, as it the case with existing biomarker for IPF:
KL-6, SP-A, and SP-D. The serum markers for IPF are
similar to those for type II pneumocytes; it is possible that
these biomarkers reflect type II pneumocyte activity.
A concern regarding serum biomarkers is that elevated
levels of some markers can be found in IPF as well as in
Samukawa et al. BMC Pulmonary Medicine 2012, 12:55 Page 6 of 7
http://www.biomedcentral.com/1471-2466/12/55malignancies, while these diseases may coincide. Serum
levels of KL-6 or VEGF were reported to be increased in
patients with IPF but also in lung cancer patients
[25,26]. The production of SP-A and SP-D by lung
adenocarcinoma cells obtained from malignant pleural
effusions has also been previously reported [27]. In lung
tumors, the sensitivity and specificity of napsin A immu-
nostaining are high for identifying adenocarcinomas
[12,13,28-30]. We compared the serum levels of napsin
A, KL-6, SP-A, and SP-D in patients with IPF and pri-
mary pulmonary adenocarcinomas. The ROC curves
demonstrated that napsin A, KL-6 and SP-D were super-
ior to SP-A as serum markers distinguishing IPF from
adenocarcinomas. The limitation in falsely positive cases
with lung cancer may be able to be corrected by using in
combination.
In addition to type II pneumocytes, napsin A is
expressed in the epithelium of the proximal and convo-
luted tubules of the kidney [31]. In this study, none of
the subjects with IPF, lung cancer, or controls exhibited
any signs of renal dysfunction or renal cell carcinoma.
Serum napsin A levels of patients with kidney disease
indicated no elevation compared with those of control
subjects. Therefore, it is unlikely that our data were
influenced by kidney disease.
There were some limitations in this study. The study
was retrospective and included only limited numbers of
patients. The role of napsin A in the pathogenesis of
lung disease is unknown, and it is possible that several
other diseases including other types of ILD and pneumo-
nia can cause an increase in serum napsin A levels.
Therefore, a large cohort study will be required to con-
firm our results. We will also need to clarify the relation-
ship of these markers to the histological patterns of ILD.
Conclusions
We have shown that napsin A is found in increased
quantities in the circulation of patients with IPF, in
whom the levels correlate with those of KL-6, SP-A,
SP-D, and lung function. Napsin A is superior to KL-6,
SP-A and SP-D for distinguishing IPF from controls.
Although these findings do not allow us to determine
whether napsin A is useful for predicting the outcome
in IPF yet, they support the hypothesis that napsin A is
a candidate biomarker for diagnosing the presence of
disease in an individual.
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